Teva Beats Q2 Estimates, Tightens 2025 EPS Range on Branded-Drug Surge

Teva Pharmaceutical Industries reported second-quarter revenue of $4.18 billion, essentially flat year on year, while adjusted earnings rose to $0.66 a share, topping the $0.62 consensus compiled by LSEG. GAAP net income reached $283 million. The world’s largest generic drugmaker logged its 10th straight quarter of annual revenue growth, buoyed by strong performances from key branded medicines Austedo for Huntington’s disease and tardive dyskinesia, migraine therapy Ajovy, and schizophrenia treatment Uzedy. Sales of Austedo jumped 22 % in the United States to $495 million, while Ajovy climbed 53 % to $63 million and Uzedy more than doubled to $54 million. Teva said its innovative portfolio now accounts for the bulk of growth, offsetting weaker generic volumes, particularly in the U.S. and following the divestment of its Japanese venture earlier this year. After the beat, the company narrowed its full-year adjusted earnings forecast to $2.50–$2.65 a share from $2.45–$2.65 and maintained guidance for revenue of $16.8–$17.2 billion and free cash flow of $1.6–$1.9 billion. Management reiterated plans to reach a 30 % operating margin by 2027 through cost-cutting and continued expansion of high-value products and biosimilars.